Feasibility of transplanting human bone marrow mesenchymal stem cells into manganese poisoning rats

doi:10.3969/j.issn.2095-4344.0471

Abstract

Abstract:

BACKGROUND: Studies have shown that bone marrow mesenchymal stem cells (BMSCs) can treat central nervous system diseases. BMSCs have the function of self-renewal and differentiation into a variety of neural cell types. BMSCs with self-renewal and multi-directional differentiation abilities can successfully differentiate into dopaminergic neurons after transplantation into an animal model.
OBJECTIVE: To observe the effect of transplanted BMSCs on behavior and dopaminergic neurons in rats with manganese poisoning.
METHODS: Rat models of manganese poisoning were constructed by intraperitoneal injection of MnCl2•4H2O into Sprague-Dawley rats. The model rats were then randomly divided into two groups, BMSCs and phosphate buffered solution (PBS) control group, and 5 μL of passage 3 human BMSCs suspension or equivalent PBS was transplanted into the right striatum of the manganese poisoning rats. One month after transplantation, the rats were subjected to behavioral assessment. The differentiation of BMSCs was observed by immunofluorescence. The contents of dopamine, brain-derived neurotrophic factor, glial cell-derived neurotrophic factor in the right striatum of rats were detected by ELISA.
RESULTS AND CONCLUSION: The behavioral score of the BMSCs treated group was significantly lower than that of the PBS control group after transplantation (P < 0.05). Double-labeled positive cells for human-specific nuclear antigen/tyrosine hydroxylase (hNUC/TH) and human-specific nuclear antigen/glial cell-derived acidic protein (hNUC/GFAP) were observed in the BMSCs treated group after transplantation. Meanwhile, hNUC/TH and hNUC/GFAP double-labeled positive cells were undetected in the PBS control group after transplantation. The expression levels of dopamine, brain-derived neurotrophic factor, glial cell-derived neurotrophic factor in the BMSCs treated group were higher than those in the PBS control group. This suggests that BMSCs can improve the behavior of manganese poisoning rats and can differentiate into dopaminergic neurons and astrocytes.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Cell Transplantation, Mesenchymal Stem Cells, Manganese Poisoning

CLC Number:

R394.2

Guo Shu-han, Song Ping-ping, Chen Ceng-ceng, Tian Yu-tian, Fan Xiao-li, Yan Yong-jian. Feasibility of transplanting human bone marrow mesenchymal stem cells into manganese poisoning rats[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(9): 1402-1406.

Figures/Tables 2

References

[1] Stanwood GD, Leitch DB, Savchenko V, et al. Manganese exposure is cytotoxic and alters dopaminergic and GABAergic neurons within the basal ganglia. J Neurochem. 2009;110(1): 378-389.

[2] Tuschl K, Clayton PT, Gospe SM Jr, et al. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet. 2012;90(3):457-466.

[3] Xiong N, Yang H, Liu L, et al. bFGF promotes the differentiation and effectiveness of human bone marrow mesenchymal stem cells in a rotenone model for Parkinson's disease. Environ Toxicol Pharmacol. 2013;36(2):411-422.

[4] Lee JK, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells reduce brain amyloid-beta deposition and accelerate the activation of microglia in an acutely induced Alzheimer's disease mouse model. Neurosci Lett. 2009; 450(2):136-141.

[5] Mazzini L, Mareschi K, Ferrero I, et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol Res. 2006;28(5):523-526.

[6] Lin YT, Chern Y, Shen CK, et al. Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models. PLoS One. 2011;6(8):e22924.

[7] Karussis D, Kassis I, Kurkalli BG, et al. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci. 2008;265(1-2):131-135.

[8] Ahmed HH, Salem AM, Atta HM, et al. Updates in the pathophysiological mechanisms of Parkinson's disease: Emerging role of bone marrow mesenchymal stem cells. World J Stem Cells. 2016;8(3):106-117.

[9] Riecke J, Johns KM, Cai C, et al. A Meta-Analysis of Mesenchymal Stem Cells in Animal Models of Parkinson's Disease. Stem Cells Dev. 2015;24(18):2082-2090.

[10] 陈忻,张楠,赵晖,等. 鱼藤酮致帕金森病大鼠行为学与黑质病理损伤的关系[J]. 中国神经精神疾病杂志,2008,34(4):232-234.

[11] Han F, Wang W, Chen B, et al. Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson's disease. Cytotherapy. 2015;17(5):665-679.

[12] Yang F, Liu Y, Tu J, et al. Activated astrocytes enhance the dopaminergic differentiation of stem cells and promote brain repair through bFGF. Nat Commun. 2014;5:5627.

[13] Huang CC. Parkinsonism induced by chronic manganese intoxication--an experience in Taiwan. Chang Gung Med J. 2007;30(5):385-395.

[14] de Bie RM, Gladstone RM, Strafella AP, et al. Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. Arch Neurol. 2007;64(6): 886-889.

[15] Guilarte TR, Burton NC, McGlothan JL, et al. Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem. 2008; 107(5):1236-1247.

[16] Liu X, Sullivan KA, Madl JE, et al. Manganese-induced neurotoxicity: the role of astroglial-derived nitric oxide in striatal interneuron degeneration. Toxicol Sci. 2006;91(2): 521-531.

[17] Dorman DC, Struve MF, Clewell HJ 3rd, et al. Application of pharmacokinetic data to the risk assessment of inhaled manganese. Neurotoxicology. 2006;27(5):752-764.

[18] Anderson JG, Cooney PT, Erikson KM. Inhibition of DAT function attenuates manganese accumulation in the globus pallidus. Environ Toxicol Pharmacol. 2007;23(2):179-184.

[19] Lu L, Zhao C, Liu Y, et al. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease. Brain Res Brain Res Protoc. 2005;15(1):46-51.

[20] Lindvall O, Wahlberg LU. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp Neurol. 2008;209(1):82-88.

[21] Du Y, Zhang X, Tao Q, et al. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease. Neurodegener Dis. 2013;11(3):113-128.

[22] Hoban DB, Howard L, Dowd E. GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease. Neuroscience. 2015;303:402-411.

[23] Peaire AE, Takeshima T, Johnston JM, et al. Production of dopaminergic neurons for cell therapy in the treatment of Parkinson's disease. J Neurosci Methods. 2003;124(1):61-74.

[24] Deierborg T, Soulet D, Roybon L, et al. Emerging restorative treatments for Parkinson's disease. Prog Neurobiol. 2008; 85(4):407-432.

[25] Ma S, Xie N, Li W, et al. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014;21(2):216-225.

[26] Boomsma RA, Geenen DL. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PLoS One. 2012;7(4):e35685.

[27] Hung SC, Pochampally RR, Chen SC, et al. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells. 2007;25(9):2363-2370.

[28] Chang MC, Tsao CH, Huang WH, et al. Conditioned medium derived from mesenchymal stem cells overexpressing HPV16 E6E7 dramatically improves ischemic limb. J Mol Cell Cardiol. 2014;72:339-349.

[29] Burlacu A, Grigorescu G, Rosca AM, et al. Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro. Stem Cells Dev. 2013;22(4):643-653.

[30] Li GH,Yu FB,Gao HJ,et al.Bone marrow mesenchymal stem cell therapy in ischemic stroke: mechanisms of action and treatment optimization strategies. Neural Regen Res. 2016;11 (6): 1015-1024.

[31] Windmolders S, De Boeck A, Koninckx R, et al. Mesenchymal stem cell secreted platelet derived growth factor exerts a pro-migratory effect on resident Cardiac Atrial appendage Stem Cells. J Mol Cell Cardiol. 2014;66:177-188.